---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-002002"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T20:45:26.517623+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ArriVent reports FY2024 net loss $80.5M; cash $266.5M; Phase 3 trial enrollment achieved

## Summary
- Cash and investments of $266.5M as of Dec 31, 2024; expected to fund operations into 2026.
- Net loss $80.5M for FY2024 vs $69.3M in FY2023; R&D expense $79.0M.
- Global pivotal Phase 3 FURVENT study for firmonertinib in EGFR exon20ins NSCLC reached target enrollment of 375 patients.
- Selected next-generation ADC candidate ARR-002 for IND-enabling studies; in-licensed ARR-217 (MRG007) from Lepu Biopharma.
- Plan to provide update on firmonertinib in EGFR PACC mutant NSCLC in H1 2025; top-line Phase 3 data expected in Q2 2025.

## SEC filing metadata
- accession: 0001558370-25-002002
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000155837025002002/0001558370-25-002002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000155837025002002/avbp-20250303x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-002002
- JSON: https://secwatch.observer/filing/0001558370-25-002002.json
- Plain text: https://secwatch.observer/filing/0001558370-25-002002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.